Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Inotersen Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy ID_CHS_27732025_1026

    Inotersen (Tegsedi)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_27732025_1026 alerts

    Get alerted when Policy ID_CHS_27732025_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for inotersen (Tegsedi) to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults, subject to diagnostic, clinical, specialist, and authorization criteria.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyInotersen (Tegsedi)
    Policy CodePolicy ID_CHS_27732025_1026
    Change TypeNo material change
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit prior authorization with confirmation of a pathogenic TTR gene variant, clinical documentation, and required specialist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum age
    12 moInitial authorization
    12 moContinuation authorization
    TTR variantGenetic confirmation
    6Prohibited therapies

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    TNState

    Coverage Criteria

    Initial Therapy Criteria

    Covered for 12 months when all of the following criteria are met:

    Initial therapy criteria

    • Age: Member is 18 years of age or older.>= 18 years
    • Genetic confirmation: The diagnosis is confirmed by detection of a pathogenic variant in the TTR gene.Pathogenic TTR variant detected
    • Clinical manifestations: Member exhibits clinical manifestations of hereditary transthyretin-mediated amyloidosis-associated polyneuropathy (ATTR-FAP), such as amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.Clinical manifestations present
    • No prohibited combination: The requested medication will not be used in combination with vutrisiran (Amvuttra), patisiran (Onpattro), eplontersen (Wainua), tafamidis meglumine (Vyndaqel), tafamidis (Vyndamax), or acoramidis (Attruby).No listed concomitant therapy

    Continuation Therapy Criteria

    Covered for 12 months for continuation therapy when all of the following criteria are met:

    Continuation therapy criteria

    • Prior authorization criteria: Member must have met all initial authorization criteria.All initial criteria met
    • Beneficial response: Member must have demonstrated a beneficial response to treatment with the requested medication compared to baseline, such as improvement in neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, or manual grip strength.Beneficial response compared with baseline

    Authorization excludes combination use of inotersen with vutrisiran (Amvuttra), patisiran (Onpattro), eplontersen (Wainua), tafamidis meglumine (Vyndaqel), tafamidis (Vyndamax), or acoramidis (Attruby).

    Coverage is limited to the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. All other indications are considered experimental/investigational and not medically necessary.

    Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial coverage of Tegsedi (inotersen) for hereditary transthyretin-mediated amyloidosis polyneuropathy in adults. Authorization may be granted for 12 months when all initial criteria are met.

    • Member is 18 years of age or older.
    • Diagnosis is confirmed by detection of a pathogenic variant in the TTR gene.
    • Member exhibits clinical manifestations of ATTR-FAP, such as amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.
    • Tegsedi will not be used in combination with vutrisiran (Amvuttra), patisiran (Onpattro), eplontersen (Wainua), tafamidis meglumine (Vyndaqel), tafamidis (Vyndamax), or acoramidis (Attruby).
    Prior Authorization

    Continuation Prior Authorization

    Reauthorization may be granted for 12 months when the member previously met all initial authorization criteria and has demonstrated beneficial response to Tegsedi compared with baseline.

    Therapy Background

    Inotersen (Tegsedi) is covered for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults, also called transthyretin-type familial amyloid polyneuropathy (ATTR-FAP). Authorization may be granted for 12 months when the member is 18 years of age or older, has a pathogenic TTR gene variant, and exhibits clinical manifestations such as amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.

    Clinical Terms and Measures

    ATTR-FAP
    DefinitionTransthyretin-type familial amyloid polyneuropathy.
    Also calledHereditary transthyretin-mediated amyloidosis-associated polyneuropathy.
    Clinical contextClinical manifestations may include amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.
    mNIS+7
    DefinitionThe modified Neuropathy Impairment Scale+7 (mNIS+7) composite score.
    UseOne measure that may demonstrate improvement in neuropathy severity and the rate of disease progression during continuation therapy.

    Initial Authorization Criteria

    Initial Authorization

    Authorization of 12 months may be granted when all initial criteria are met:

    Initial authorization criteria

    • Age: Member is 18 years of age or older.>= 18 years
    • Genetic confirmation: The diagnosis is confirmed by detection of a pathogenic variant in the TTR gene.Pathogenic TTR variant detected
    • Clinical manifestations: Member exhibits clinical manifestations of hereditary transthyretin-mediated amyloidosis-associated polyneuropathy (ATTR-FAP), including amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.

    Continuation Authorization Criteria

    Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when all continuation criteria are met:

    Continuation authorization criteria

    • Prior initial eligibility: Member must have met all initial authorization criteria.All initial criteria met
    • Documented clinical benefit: Member must have demonstrated a beneficial response to treatment with the requested medication compared to baseline, such as improvement in neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, or manual grip strength.Beneficial response compared with baseline

      Submit clinical documentation supporting the response to treatment.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyInotersen (Tegsedi)
    Policy CodePolicy ID_CHS_27732025_1026
    Change TypeNo material change
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit prior authorization with confirmation of a pathogenic TTR gene variant, clinical documentation, and required specialist involvement.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Provider RequirementsTherapy BackgroundClinical Terms and MeasuresInitial Authorization CriteriaContinuation Authorization Criteria
    • Member must have met all initial authorization criteria.
    • Documentation must demonstrate beneficial response, such as improvement in neuropathy severity or rate of disease progression measured by mNIS+7, Norfolk QoL-DN total score, PND score, FAP disease stage, or manual grip strength.
    Documentation Required

    Initial Request Documentation

    Submit the documentation necessary to initiate prior authorization review. Initial requests must establish the qualifying diagnosis, clinical manifestations, signs and symptoms, appropriate specialist involvement, and the requested treatment.

    • Testing or analysis confirming a pathogenic variant in the TTR gene.
    • Medical records demonstrating clinical manifestations of ATTR-FAP, including amyloid deposition in biopsy specimens, TTR protein variants in serum, or progressive peripheral sensory-motor polyneuropathy.
    • Medical records confirming signs and symptoms of polyneuropathy.
    • Documentation identifying the requested Tegsedi treatment and supporting the treatment request.
    • Documentation of the prescribing specialist or consultation when applicable.
    Documentation Required

    Continuation Documentation

    For continuation requests, submit chart notes or medical records that support clinical benefit from the requested medication compared with baseline.

    • Records may document improvement in neuropathy severity or disease progression using measures such as mNIS+7, Norfolk QoL-DN total score, PND score, FAP disease stage, or manual grip strength.
    • The member must have met all initial authorization criteria.

    Unsupported block type: info

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Authorization context
    Improvement compared with baseline demonstrated by mNIS+7 may support a beneficial response to treatment.
    Norfolk QoL-DN
    DefinitionThe Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score.
    UseOne possible measure of beneficial response during continuation therapy.
    Authorization contextImprovement compared with baseline demonstrated by the Norfolk QoL-DN total score may support continued treatment.
    Clinical manifestations present
  1. No prohibited combination: The requested medication will not be used in combination with vutrisiran (Amvuttra), patisiran (Onpattro), eplontersen (Wainua), tafamidis meglumine (Vyndaqel), tafamidis (Vyndamax), or acoramidis (Attruby).No listed concomitant therapy